Cargando…
An Open Label, Randomised Trial of Artesunate+Amodiaquine, Artesunate+Chlorproguanil-Dapsone and Artemether-Lumefantrine for the Treatment of Uncomplicated Malaria
BACKGROUND: Artesunate+amodiaquine (AS+AQ) and artemether-lumefantrine (AL) are now the most frequently recommended first line treatments for uncomplicated malaria in Africa. Artesunate+chlorproguanil-dapsone (AS+CD) was a potential alternative for treatment of uncomplicated malaria. A comparison of...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2008
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2430614/ https://www.ncbi.nlm.nih.gov/pubmed/18575626 http://dx.doi.org/10.1371/journal.pone.0002530 |
_version_ | 1782156417285750784 |
---|---|
author | Owusu-Agyei, Seth Asante, Kwaku Poku Owusu, Ruth Adjuik, Martin Amenga-Etego, Stephen Dosoo, David Kwame Gyapong, John Greenwood, Brian Chandramohan, Daniel |
author_facet | Owusu-Agyei, Seth Asante, Kwaku Poku Owusu, Ruth Adjuik, Martin Amenga-Etego, Stephen Dosoo, David Kwame Gyapong, John Greenwood, Brian Chandramohan, Daniel |
author_sort | Owusu-Agyei, Seth |
collection | PubMed |
description | BACKGROUND: Artesunate+amodiaquine (AS+AQ) and artemether-lumefantrine (AL) are now the most frequently recommended first line treatments for uncomplicated malaria in Africa. Artesunate+chlorproguanil-dapsone (AS+CD) was a potential alternative for treatment of uncomplicated malaria. A comparison of the efficacy and safety of these three drug combinations was necessary to make evidence based drug treatment policies. METHODS: Five hundred and thirty-four, glucose-6-phosphate dehydrogenase (G6PD) normal children were randomised in blocks of 15 to the AS+AQ, AL or AS+CD groups. Administration of study drugs was supervised by project staff and the children were followed up at r home on days 1,2,3,7,14 and 28 post treatment. Parasitological and clinical failures and adverse events were compared between the study groups. MAIN FINDINGS: In a per-protocol analysis, the parasitological and clinical failure rate at day 28 post treatment (PCF28) was lower in the AS+AQ group compared to the AL or AS+CD groups (corrected for re-infections: 6.6% vs 13.8% and 13.8% respectively, p = 0.08; uncorrected: 14.6% vs 27.6% and 28.1% respectively, p = 0.005). In the intention to treat analysis, the rate of early treatment failure was high in all three groups (AS+AQ 13.3%; AL 15.2%; and AS+CD 9.3%, p = 0.2) primarily due to vomiting. However, the PCF28 corrected for re-infection was lower, though not significantly, in the AS+AQ group compared to the AL or the AS+CD groups (AS+AQ 18.3%; AL 24.2%; AS+CD 20.8%, p = 0.4) The incidence of adverse events was comparable between the groups. CONCLUSIONS: AS+AQ is an appropriate first line treatment for uncomplicated malaria in Ghana and possibly in the neighbouring countries in West Africa. The effectiveness of AL in routine programme conditions needs to be studied further in West Africa. TRIAL REGISTRATION: ClinicalTrials.gov NCT00119145 |
format | Text |
id | pubmed-2430614 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2008 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-24306142008-06-25 An Open Label, Randomised Trial of Artesunate+Amodiaquine, Artesunate+Chlorproguanil-Dapsone and Artemether-Lumefantrine for the Treatment of Uncomplicated Malaria Owusu-Agyei, Seth Asante, Kwaku Poku Owusu, Ruth Adjuik, Martin Amenga-Etego, Stephen Dosoo, David Kwame Gyapong, John Greenwood, Brian Chandramohan, Daniel PLoS One Research Article BACKGROUND: Artesunate+amodiaquine (AS+AQ) and artemether-lumefantrine (AL) are now the most frequently recommended first line treatments for uncomplicated malaria in Africa. Artesunate+chlorproguanil-dapsone (AS+CD) was a potential alternative for treatment of uncomplicated malaria. A comparison of the efficacy and safety of these three drug combinations was necessary to make evidence based drug treatment policies. METHODS: Five hundred and thirty-four, glucose-6-phosphate dehydrogenase (G6PD) normal children were randomised in blocks of 15 to the AS+AQ, AL or AS+CD groups. Administration of study drugs was supervised by project staff and the children were followed up at r home on days 1,2,3,7,14 and 28 post treatment. Parasitological and clinical failures and adverse events were compared between the study groups. MAIN FINDINGS: In a per-protocol analysis, the parasitological and clinical failure rate at day 28 post treatment (PCF28) was lower in the AS+AQ group compared to the AL or AS+CD groups (corrected for re-infections: 6.6% vs 13.8% and 13.8% respectively, p = 0.08; uncorrected: 14.6% vs 27.6% and 28.1% respectively, p = 0.005). In the intention to treat analysis, the rate of early treatment failure was high in all three groups (AS+AQ 13.3%; AL 15.2%; and AS+CD 9.3%, p = 0.2) primarily due to vomiting. However, the PCF28 corrected for re-infection was lower, though not significantly, in the AS+AQ group compared to the AL or the AS+CD groups (AS+AQ 18.3%; AL 24.2%; AS+CD 20.8%, p = 0.4) The incidence of adverse events was comparable between the groups. CONCLUSIONS: AS+AQ is an appropriate first line treatment for uncomplicated malaria in Ghana and possibly in the neighbouring countries in West Africa. The effectiveness of AL in routine programme conditions needs to be studied further in West Africa. TRIAL REGISTRATION: ClinicalTrials.gov NCT00119145 Public Library of Science 2008-06-25 /pmc/articles/PMC2430614/ /pubmed/18575626 http://dx.doi.org/10.1371/journal.pone.0002530 Text en Owusu-Agyei et al. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited. |
spellingShingle | Research Article Owusu-Agyei, Seth Asante, Kwaku Poku Owusu, Ruth Adjuik, Martin Amenga-Etego, Stephen Dosoo, David Kwame Gyapong, John Greenwood, Brian Chandramohan, Daniel An Open Label, Randomised Trial of Artesunate+Amodiaquine, Artesunate+Chlorproguanil-Dapsone and Artemether-Lumefantrine for the Treatment of Uncomplicated Malaria |
title | An Open Label, Randomised Trial of Artesunate+Amodiaquine, Artesunate+Chlorproguanil-Dapsone and Artemether-Lumefantrine for the Treatment of Uncomplicated Malaria |
title_full | An Open Label, Randomised Trial of Artesunate+Amodiaquine, Artesunate+Chlorproguanil-Dapsone and Artemether-Lumefantrine for the Treatment of Uncomplicated Malaria |
title_fullStr | An Open Label, Randomised Trial of Artesunate+Amodiaquine, Artesunate+Chlorproguanil-Dapsone and Artemether-Lumefantrine for the Treatment of Uncomplicated Malaria |
title_full_unstemmed | An Open Label, Randomised Trial of Artesunate+Amodiaquine, Artesunate+Chlorproguanil-Dapsone and Artemether-Lumefantrine for the Treatment of Uncomplicated Malaria |
title_short | An Open Label, Randomised Trial of Artesunate+Amodiaquine, Artesunate+Chlorproguanil-Dapsone and Artemether-Lumefantrine for the Treatment of Uncomplicated Malaria |
title_sort | open label, randomised trial of artesunate+amodiaquine, artesunate+chlorproguanil-dapsone and artemether-lumefantrine for the treatment of uncomplicated malaria |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2430614/ https://www.ncbi.nlm.nih.gov/pubmed/18575626 http://dx.doi.org/10.1371/journal.pone.0002530 |
work_keys_str_mv | AT owusuagyeiseth anopenlabelrandomisedtrialofartesunateamodiaquineartesunatechlorproguanildapsoneandartemetherlumefantrineforthetreatmentofuncomplicatedmalaria AT asantekwakupoku anopenlabelrandomisedtrialofartesunateamodiaquineartesunatechlorproguanildapsoneandartemetherlumefantrineforthetreatmentofuncomplicatedmalaria AT owusuruth anopenlabelrandomisedtrialofartesunateamodiaquineartesunatechlorproguanildapsoneandartemetherlumefantrineforthetreatmentofuncomplicatedmalaria AT adjuikmartin anopenlabelrandomisedtrialofartesunateamodiaquineartesunatechlorproguanildapsoneandartemetherlumefantrineforthetreatmentofuncomplicatedmalaria AT amengaetegostephen anopenlabelrandomisedtrialofartesunateamodiaquineartesunatechlorproguanildapsoneandartemetherlumefantrineforthetreatmentofuncomplicatedmalaria AT dosoodavidkwame anopenlabelrandomisedtrialofartesunateamodiaquineartesunatechlorproguanildapsoneandartemetherlumefantrineforthetreatmentofuncomplicatedmalaria AT gyapongjohn anopenlabelrandomisedtrialofartesunateamodiaquineartesunatechlorproguanildapsoneandartemetherlumefantrineforthetreatmentofuncomplicatedmalaria AT greenwoodbrian anopenlabelrandomisedtrialofartesunateamodiaquineartesunatechlorproguanildapsoneandartemetherlumefantrineforthetreatmentofuncomplicatedmalaria AT chandramohandaniel anopenlabelrandomisedtrialofartesunateamodiaquineartesunatechlorproguanildapsoneandartemetherlumefantrineforthetreatmentofuncomplicatedmalaria AT owusuagyeiseth openlabelrandomisedtrialofartesunateamodiaquineartesunatechlorproguanildapsoneandartemetherlumefantrineforthetreatmentofuncomplicatedmalaria AT asantekwakupoku openlabelrandomisedtrialofartesunateamodiaquineartesunatechlorproguanildapsoneandartemetherlumefantrineforthetreatmentofuncomplicatedmalaria AT owusuruth openlabelrandomisedtrialofartesunateamodiaquineartesunatechlorproguanildapsoneandartemetherlumefantrineforthetreatmentofuncomplicatedmalaria AT adjuikmartin openlabelrandomisedtrialofartesunateamodiaquineartesunatechlorproguanildapsoneandartemetherlumefantrineforthetreatmentofuncomplicatedmalaria AT amengaetegostephen openlabelrandomisedtrialofartesunateamodiaquineartesunatechlorproguanildapsoneandartemetherlumefantrineforthetreatmentofuncomplicatedmalaria AT dosoodavidkwame openlabelrandomisedtrialofartesunateamodiaquineartesunatechlorproguanildapsoneandartemetherlumefantrineforthetreatmentofuncomplicatedmalaria AT gyapongjohn openlabelrandomisedtrialofartesunateamodiaquineartesunatechlorproguanildapsoneandartemetherlumefantrineforthetreatmentofuncomplicatedmalaria AT greenwoodbrian openlabelrandomisedtrialofartesunateamodiaquineartesunatechlorproguanildapsoneandartemetherlumefantrineforthetreatmentofuncomplicatedmalaria AT chandramohandaniel openlabelrandomisedtrialofartesunateamodiaquineartesunatechlorproguanildapsoneandartemetherlumefantrineforthetreatmentofuncomplicatedmalaria |